Nearly 2,000 people have been vaccinated! "Lizhu Bio's recombinant novel coronavirus fusion protein vaccine" is being promoted and vaccinated in our city

Time Posted：2022-12-11 23:49

Recently, a new vaccine jointly developed by Lizhu Bio and the Institute of Biophysics, Chinese Academy of Sciences, the "Lizhu Bio Recombinant Novel Coronavirus Fusion Protein Vaccine," has been officially promoted and vaccinated in our city, with nearly 2,000 people already vaccinated. At the Lizhu Group Limin Pharmaceutical Factory, the reporter met Huang Wenhua, the factory director and senior engineer. According to him, Lizhu Bio launched the Lizhu Bio Recombinant Novel Coronavirus Fusion Protein Vaccine project in July 2020. In September 2022, the vaccine developed and produced by this project was officially included in the national COVID-19 immunization program.

The "Universal Slow-onset Disease Prevention and Treatment" project was selected as one of the top 100 citizen satisfaction projects, using medicine to benefit the people and accelerate rural revitalization.

Time Posted：2022-12-09 20:37

To cultivate and practice the core socialist values, and to establish and promote a group of advanced role models who inherit the fine traditional Chinese virtues and embody the spirit of care, and to promote the concept of care to the hearts of the people, the Shenzhen Civilization Office and the Shenzhen Care Office recently organized the 19th Shenzhen Care Action series selection activities. Health Yuan (600380) Pharmaceutical Group, a local comprehensive pharmaceutical company in Shenzhen, won the honorary title of "Top 100 Citizen Satisfaction Projects" in the 19th Shenzhen Care Action for its outstanding contributions in rural revitalization through its "Affordable Chronic Disease Prevention and Treatment" project.

A historic breakthrough: Health Yuan's "breath" reigns supreme

Time Posted：2022-12-06 20:30

Condensing the process of developing and launching a new drug with a breakthrough mission always brings a thrilling sense of excitement, like hearing thunder in silence. In 2014, academician Zhong Nanshan of the Chinese Academy of Engineering initiated a clinical research project on tobramycin inhalation solution. The reason for launching this project was the lack of clinical guidelines and relevant antibacterial drugs with indications in China, in the face of the increasing incidence of bronchiectasis. The fact that the "top figure" in the field of respiratory medicine in China attaches so much importance to tobramycin shows that this commonly used antibiotic is not so ordinary; perhaps it is just a matter of "how to use it".

The First Bay Area Skin Health Forum was successfully held, with Tai Tai Pharmaceutical actively promoting the integrated treatment of chloasma using both Chinese and Western medicine.

Time Posted：2022-11-30 21:05

To further enhance the diagnostic and treatment capabilities of dermatologists in Shenzhen and contribute to the construction of a healthy ecosystem in areas such as remote internet-based dermatology based on skin imaging and targeted therapy for skin diseases, the First Bay Area Skin Health Forum and the 2022 Annual Meeting of the Dermatology Professional Committee of the Shenzhen Health Management Association, hosted by the Dermatology Professional Committee of the Shenzhen Health Management Association and co-organized by Tai Tai Pharmaceutical, a leading enterprise in the field of oral beauty in China, and "Health 160," was successfully held in Shenzhen on November 26. Focusing on Clinical Needs and In-depth Topics on Skin Health The "Shenzhen Action Plan for Cultivating and Developing a Big Health Industry Cluster (2022-2025)" proposes to "strive to build a big health manufacturing industry ecosystem with a reasonable industrial structure and a complete industrial chain, and build a health service demonstration center radiating the Guangdong-Hong Kong-Macao Greater Bay Area," and "strive to become a national gathering highland for the development of the big health industry." Under the guidance of this significant policy, Tai Tai Pharmaceutical, a professional brand focusing on the internal conditioning and beauty of Chinese women for 30 years, actively responded to the call of the Healthy China 2030 strategic goal, assisted in hosting the First Bay Area Skin Health Forum and the 2022 Annual Meeting of the Dermatology Professional Committee of the Shenzhen Health Management Association, focusing on important topics in dermatology, discussing feasible solutions for the diagnosis and treatment of chloasma, and building a good academic exchange platform for the vigorous development of clinical dermatology and discipline construction in Shenzhen, the Bay Area, and even the whole country. This forum not only focuses on the clinical diagnostic and treatment needs in the field of dermatology, but also aims to promote the system level of production, education, research, and application, and to create a highland for the development of dermatology. The forum attracted the enthusiastic participation of dozens of dermatology experts from Beijing, Guangzhou, Dalian, Changsha, Nanchang, and Shenzhen. Among them, the Hong Kong University Shenzhen Hospital, the Second People's Hospital of Shenzhen, the Shenzhen University Affiliated Huainan Hospital, and the Huazhong University of Science and Technology Union Shenzhen Hospital, as members of the Shenzhen Union of Rare and Difficult Skin Diseases, attended this academic discussion.

Development dynamics of enterprises invested in by LiZhu Group, a subsidiary of Jiankang Yuan Holdings (October 2022 edition)

Time Posted：2022-11-24 14:11

Artificial Intelligence (AI) Field InfiniAI Pharmaceuticals Publishes Paper on Automated Molecular Structure Recognition Tool MolMiner In September 2022, Beijing InfiniAI Pharmaceuticals Co., Ltd. (InfiniAI Pharmaceuticals) published a paper on the automated molecular structure recognition tool MolMiner in the JCIM journal. MolMiner is a tool for automatically identifying chemical molecular structures, jointly developed by InfiniAI Pharmaceuticals and Peking University. It is a functional module in the PharmaMind® innovative drug R&D platform. Currently, MolMiner has nearly 8,000 registered users, including 31 enterprise-level users, and maintains an average daily active user count of over 60.

World COPD Day | Finding 1/14 of the population

Time Posted：2022-11-16 16:42

First inhaled antibiotic! Developed specifically for Chinese patients, Jianketo officially enters clinical use

Time Posted：2022-11-11 16:47

On November 10, 2022, the "Developed for Chinese Patients" 2022 Jianketo® New Drug Launch Conference of Healthy Yuan Pharmaceutical Group (600380.SH) was held simultaneously in Shenzhen, Shanghai, and Beijing, combining online and offline methods. Many expert professors in the field of respiratory health gathered at the scene, and through keynote speeches, seminars, and roundtable discussions, they exchanged and discussed new options for the treatment of bronchiectasis around the themes of the first inhaled antibiotic and the management of bronchiectasis in China. Currently, Jianketo® tobramycin inhalation solution has completed drug production, and the first prescription has been issued and officially entered clinical use.

Congratulations! The leading enterprises and figures in high-quality development in 2022 have been announced! Dr. Jin Fang, chief scientist of HealthGen, has been selected.

Time Posted：2022-11-08 19:59

Promoting high-quality development is Shenzhen's mission and responsibility. On November 7, 2022, the leading enterprises and figures in high-quality development were announced! Dr. Jin Fang, chief scientist of HealthGen, was selected.